PF-06273340

DB12269InvestigationalSmall molecule

Pf 06273340 is under investigation in clinical trial NCT01934738 (A Study to Evaluate Safety, Toleration and Time Course of Plasma Concentration of Multiple Oral Doses of PF-06273340 in Healthy Subjects...

Mechanism: Pharmacologically active on High affinity nerve growth factor receptor, BDNF/NT-3 growth factors receptor, and NT-3 growth factor receptor
Curator reviewed
Formula / weight: C₂₃H₂₂ClN₇O₃ · 479.93 g/mol (avg)
Code names: PF06273340

Resolves to

Compound

UNIII136775ABWCAS1402438-74-7PubChem66571548

Structure

InChIKeyBPIWZDNVMQQBQX-UHFFFAOYSA-NSMILESCC(C)(CO)N1C=C(C(=O)C2=CC(NC(=O)CC3=CC=C(Cl)C=N3)=CN=C2)C2=CN=C(N)N=C12

Targets

P04629NTRK1Q16620NTRK2Q16288NTRK3

What you can answer from here — as of July 07, 2026

3Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

6+ReferencesStructured and connected to the statements they support

Which drugs share a target with PF-06273340, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account